Abstract 5147
Background
Patient rights has been developed from human rights. Human rights emerged from the Universal Declaration of Human Rights. The Declaration is a milestone document in the history of human rights (1). Today the patient’s rights have become an important issue on the political agenda. Individual’s awareness of their own rights in the health area is constantly increasing. Patient’s rights are becoming primary concern in improving quality of health care (2). Today the patient becomes the consumer (3). The most important role that nurses have is delivering quality care for the patients and also act as patient advocates. Nurses must understand the importance of patient rights. The main aim of the survey is to analyze, investigate, compare and present, the legal framework of the patient’s rights legislation in the European Union.
Methods
A literature search and review related to the patient right was conducted using PubMed, Cinahl, Medline and Google Scholar. With descriptive method we set up a theoretical framework of the patient’s rights legislation. We also use comporative method to discover the similarities and differences between legal systems and their components.
Results
Patient’s rights are in thirteen European Member States regulated by specific law - Law on patient’s rights.
Conclusions
EU Member States do not have a common legislation for patient’s rights. Patient’s rights vary from country to country. Some countries have a single law or act, others use multiple pieces of legislation. Nurses are an important voice of the patient. References: 1. Universal Declaration of Human Rights. Avalible at: Https://www.un.org/en/universal-declaration-human-rights/ (10. 4. 2019). 2. Opinion of the European Economic and Social Committee on Patients’ rights. Official Journal EU, C10/67. Avalible at: Https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:010:0067:0071:EN:PDF (10. 4. 2019). 3. OECD - Patients, Patient Organisations and the Production of Medical Science and Technology. Avalible at: Http://www.oecd.org/education/innovation-education/32126031.pdf (10. 4. 2019). 4. Kozuh M., 2016. Legal Arrangements for the Protection of Patients’ Rights: A Comparative Overview of the Regulation in the EU (Master Thesis). University of Primorska Slovenia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maja Kozuh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3252 - Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Presenter: Fernanda Costa Svedman
Session: Poster Display session 3
Resources:
Abstract
5545 - Phase Ib/II Study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy
Presenter: Jessica Hassel
Session: Poster Display session 3
Resources:
Abstract
5213 - Genomic landscape of primary malignant melanoma of esophagus
Presenter: Jie Dai
Session: Poster Display session 3
Resources:
Abstract
2716 - A phase III, randomised, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation in patients with high-risk cutaneous squamous cell carcinoma (CSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
3550 - ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy
Presenter: Marcus Butler
Session: Poster Display session 3
Resources:
Abstract
1645 - PRIME002 - Early phase II study of Azacitidine and Carboplatin priming for Avelumab in patients with advanced melanoma who are resistant to immunotherapy
Presenter: Andre Van Der Westhuizen
Session: Poster Display session 3
Resources:
Abstract
4440 - Pembrolizumab (pembro) Plus Lenvatinib (len) for First-Line Treatment of patients (pts) With Advanced Melanoma: Phase 3 LEAP-003 Study
Presenter: Alexander Eggermont
Session: Poster Display session 3
Resources:
Abstract
3454 - Proof of concept study with the histone deacetylase inhibitor vorinostat in patients with resistant BRAFV600 mutated advanced melanoma
Presenter: Sanne Huijberts
Session: Poster Display session 3
Resources:
Abstract
1832 - A phase Ia/Ib clinical study to evaluate the safety, pharmacokinetics (PK) and preliminary anti-tumor activity of FCN-159 in patients with advanced melanoma harboring NRAS-aberrant (Ia) and NRAS-mutation (Ib).
Presenter: Lu Si
Session: Poster Display session 3
Resources:
Abstract
3996 - A Phase I Clinical Trial Investigating the Therapeutic Cancer Vaccine UV1 in Combination with Pembrolizumab as First-Line Treatment of Patients with Malignant Melanoma
Presenter: Sanjiv Agarwala
Session: Poster Display session 3
Resources:
Abstract